News

  • 19 October 2022

    Sonendo, Inc. (“Sonendo”) (NYSE: SONX), a leading dental technology company and developer of the GentleWave® System, today announced that it will report financial results for the third quarter 2022 after the market close on Wednesday, November 9th, 2022. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results.

  • 18 October 2022

    Sonendo, Inc. (NYSE: SONX), a leading dental technology company and developer of the GentleWave® System, today announced the release of the GentleWave G4 System, the next generation of its innovative technology platform designed to treat tooth decay. With Sonendo's patented technology at its core, the GentleWave G4 System is designed for an optimized doctor and patient experience with a refined, simplified workflow – all while delivering the enhanced level of clean that is only available with GentleWave Technology. Broad-spectrum acoustic energy and advanced fluid dynamics deliver advanced disinfection to penetrate even the most complex anatomies, resulting in a predictable and superior level of cleaning and improved healing time.

  • 23 September 2022

    Sonendo, Inc. (NYSE: SONX), a leading dental technology company and developer of the GentleWave® System, today announced a private placement of common stock and pre-funded warrants, resulting in gross proceeds of $63 million. New and existing investors, including Pura Vida Investments, First Light Asset Management, Blue Water Life Science Advisors, ArrowMark Partners, Driehaus Capital Management, and JMR Capital participated in the financing.

  • 14 September 2022

    JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced the successful completion of patient enrollment in the ALIGN-AR Pivotal trial.

  • 8 September 2022

    Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today announces its business highlights and financial results for the six-month period ending 30 June 2022 and its outlook for the remainder of the year and beyond.